Agree, still forecast ROE above 15% 2015 but hope they can use the cash to add growth for 2016. Looking forward to feedback from the meetings this week.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%